Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) Overview 6
Therapeutics Development 7
Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) - Products under Development by Stage of Development 7
Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) - Products under Development by Therapy Area 8
Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) - Products under Development by Indication 9
Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) - Products under Development by Companies 12
Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) - Products under Development by Universities/Institutes 14
Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 19
Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) - Companies Involved in Therapeutics Development 20
Amgen Inc. 20
Handok Inc. 21
Hanmi Pharmaceuticals, Co. Ltd. 22
Merck & Co., Inc. 23
Novartis AG 24
Viking Therapeutics, Inc. 25
Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) - Drug Profiles 26
BH-03004 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
HL-5201 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
KR-69530 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
pradigastat sodium - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecules to Inhibit DGAT-1 for Dyslipidemia and Obesity - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecules to Inhibit DGAT1 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) - Dormant Projects 35
Diacylglycerol O-Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT-Related Gene Product 1 or Acyl-CoA Retinol O-Fatty-Acyltransferase or EC 2.3.1.20) - Discontinued Products 36
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 38
Disclaimer 39

List of Tables
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Stage and Mechanism of Action, H1 2016 17
Number of Products by Stage and Route of Administration, H1 2016 18
Number of Products by Stage and Molecule Type, H1 2016 19
Pipeline by Amgen Inc., H1 2016 20
Pipeline by Handok Inc., H1 2016 21
Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 22
Pipeline by Merck & Co., Inc., H1 2016 23
Pipeline by Novartis AG, H1 2016 24
Pipeline by Viking Therapeutics, Inc., H1 2016 25
Dormant Projects, H1 2016 35
Discontinued Products, H1 2016 36
Discontinued Products (Contd..1), H1 2016 37

List of Figures
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Stage and Mechanism of Actions, H1 2016 17
Number of Products by Stage and Routes of Administration, H1 2016 18
Number of Products by Stage and Molecule Type, H1 2016 19